Epigenetic therapy in lung cancer and mesothelioma

Baird, Anne-Marie, Richard, Derek J., O’Byrne, Kenneth J., & Gray, Steven G. (2015) Epigenetic therapy in lung cancer and mesothelioma. In Gray, Steven G. (Ed.) Epigenetic Cancer Therapy. Academic Press (Elsevier), Amsterdam, pp. 189-213.

View at publisher


Thoracic malignancies present a considerable global health burden with the incidence and mortality of both lung cancer and malignant pleural mesothelioma (MPM) increasing year on year. Survival rates are poor and treatment options are limited in these cancers. Several epigenetic modifications have been associated with the development of both of these diseases with alterations discriminating between MPM and adenocarcinoma (AC) of the lung. In addition, studies have suggested that epigenetic agents are effective in altering the cellular characteristics of lung and MPM cells in terms of proliferation and migration. Furthermore, it has been demonstrated that epigenetic therapy can alter a pathologically relevant gene expression profile, with one that is more associated with comparative normal tissue. Therefore agents, which target the epi-genomes of lung cancer and MPM, may provide a substantial therapeutic improvement when used in combination with current therapy or indeed benefit when used as a single treatment modality.

Impact and interest:

1 citations in Scopus
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 95340
Item Type: Book Chapter
Additional URLs:
Keywords: Nonsmall cell lung cancer; small cell lung cancer; histone modification; DNA methylation; malignant pleural mesothelioma; HDAC inhibitor; DNMT inhibitor; clinical trials
DOI: 10.1016/B978-0-12-800206-3.00009-4
ISBN: 9780128002063
Divisions: Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2015 Academic Press (Elsevier)
Deposited On: 02 May 2016 23:48
Last Modified: 04 May 2016 01:47

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page